ReviewFrontiers in immunology2016
Prospective Clinical Testing of Regulatory Dendritic Cells in Organ Transplantation.
Review in Frontiers in immunology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 46 citations in OpenAlex.
- Vaccination with poly(IC:LC) and peptide-pulsed autologous dendritic cells in patients with pancreatic cancer.Journal of hematology & oncology · 2017Trial
- Recent advances in regulatory immune cells: exploring the world beyond Tregs.Frontiers in immunology · 2025Review
- Advancing immunosuppression in liver transplantation: the role of regulatory T cells in immune modulation and graft tolerance.Clinical transplantation and research · 2024Review
- Emerging strategies for treating autoimmune disease with genetically modified dendritic cells.Cell communication and signaling : CCS · 2024Review
- Innate immune cellular therapeutics in transplantation.Frontiers in transplantation · 2023Article
- STXBP3 and GOT2 predict immunological activity in acute allograft rejection.Frontiers in immunology · 2022Article
- Clinical translation of immunomodulatory therapeutics.Advanced drug delivery reviews · 2021Review
- Regulatory Dendritic Cells, T Cell Tolerance, and Dendritic Cell Therapy for Immunologic Disease.Frontiers in immunology · 2021Review
- The Role of Regulatory Myeloid Cell Therapy in Renal Allograft Rejection.Frontiers in immunology · 2021Review
- Understanding, predicting and achieving liver transplant tolerance: from bench to bedside.Nature reviews. Gastroenterology & hepatology · 2020Review
- The Role of Epigenetics in the Chronic Sinusitis with Nasal Polyp.Current allergy and asthma reports · 2020Review
- Transplant Tolerance Induction: Insights From the Liver.Frontiers in immunology · 2020Review
- Progress in Liver Transplant Tolerance and Tolerance-Inducing Cellular Therapies.Frontiers in immunology · 2020Review
- Detection and Monitoring of Regulatory Immune Cells Following Their Adoptive Transfer in Organ Transplantation.Frontiers in immunology · 2020Review
- Impact of infection on transplantation tolerance.Immunological reviews · 2019Review
- Regulatory dendritic cells for human organ transplantation.Transplantation reviews (Orlando, Fla.) · 2019Review
- Engineering immunomodulatory biomaterials for type 1 diabetes.Nature reviews. Materials · 2019Article
- Dendritic Cells as Sensors, Mediators, and Regulators of Ischemic Injury.Frontiers in immunology · 2019Review
- Regulatory dendritic cells: profiling, targeting, and therapeutic application.Current opinion in organ transplantation · 2018Review
- Automated generation of immature dendritic cells in a single-use system.Journal of immunological methods · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Dendritic cells (DC) are rare, professional antigen-presenting cells with ability to induce or regulate alloimmune responses. Regulatory DC (DCreg) with potential to down-modulate acute and chronic inflammatory conditions that occur in organ transplantation can be generated in vitro under a variety of conditions. Here, we provide a rationale for evaluation of DCreg therapy in clinical organ transplantation with the goal of promoting sustained, donor-specific hyporesponsiveness, while lowering the incidence and severity of rejection and reducing patients' dependence on anti-rejection drugs. Generation of donor- or recipient-derived DCreg that suppress T cell responses and prolong transplant survival in rodents or non-human primates has been well-described. Recently, good manufacturing practice (GMP)-grade DCreg have been produced at our Institution for prospective use in human organ transplantation. We briefly review experience of regulatory immune therapy in organ transplantation and describe our experience generating and characterizing human monocyte-derived DCreg. We propose a phase I/II safety study in which the influence of donor-derived DCreg combined with conventional immunosuppression on subclinical and clinical rejection and host alloimmune responses will be examined in detail.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.